A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy.

Permalink
https://escholarship.org/uc/item/8cm5n943

Authors
Kaplan, Celia P
Siegel, Adam
Leykin, Yan
et al.

Publication Date
2018-12-01

DOI
10.1016/j.conctc.2018.08.005

Peer reviewed
A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy

Celia P. Kaplan a,b,*, Adam Siegel c, Yan Leykin d,e, Nynikka R. Palmer b,f, Hala Borno b,h, Jessica Bielenberg g, Jennifer Livaudais-Toman a, Charles Ryan i, Eric J. Small b,h

a Department of Medicine, Division of General Internal Medicine, University of California, San Francisco, USA
b Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA
c Aurora Health Center St Luke's Hospital, Milwaukee, WI, USA
d Department of Psychiatry, University of California, San Francisco, USA
e PhD Clinical Psychology Program, Palo Alto University, USA
f Department of Medicine, Division of General Internal Medicine at Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, USA
g NORC at the University of Chicago, USA
h Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, USA
i Department of Medicine, Division of Hematology/Oncology and Bone Marrow Transplant, University of Minnesota, USA

ABSTRACT

Background: To address limitations in recruitment and enrollment of diverse, low-literacy patients into prostate cancer clinical trials, we evaluated the feasibility, acceptability, and efficacy of an English and Spanish, Internet-based, multilevel recruitment intervention.

Methods: Intervention components included (1) a low-literacy, bilingual, automated, Internet-based clinical trial matching tool; (2) a bilingual nurse who assisted individuals with questions and enrollment; and (3) a targeted, Internet-based advertising campaign. We evaluated (a) completion of matching tool, (b) expression of interest in a clinical trial, (c) number of patients who matched to at least one clinical trial, (d) discussion of risks and benefits of clinical trials (via follow-up interviews), and (e) effect of the advertising on completing the matching tool. Feasibility, acceptability, and preliminary estimates of efficacy were measured through user engagement with the matching tool and subsequent qualitative interviews with these same users.

Results: During the 28-week study period, 523 users provided demographic information, 263 were identified with prostate cancer, 192 (73%) matched to at least one clinical trial, and 29 (15.1%) of those who matched provided contact information. During the study period, 17 prostate cancer clinical trials were available for matching. We completed follow-up interviews with 14 of the 29 men who provided contact information. Of the 14, 85.7% discussed the risks and benefits of clinical trials with their physician, and 35.7% enrolled in a clinical trial. The Internet-based advertising campaign resulted in an increased number of matching tool completions.

Conclusions: Our study demonstrates that an Internet-based clinical trial matching tool that is advertised using a targeted Internet-based campaign can provide an effective means to reach diverse, low-literacy patients. When implemented at scale and over a longer duration, such interventions may help increase trial participation among underrepresented populations.

A R T I C L E  I N F O

Keywords:
Internet recruitment
Clinical trials participation
Prostate cancer
Underserved populations

1. Introduction

Advances in cancer diagnosis and treatment depend on the voluntary participation of diverse and representative patients in clinical trials [1]. However, in the United States, less than 5% of all eligible adult cancer patients participate in clinical trials [2]. Clinical trial enrollees tend to be well-educated, middle class, and Caucasian, and as a result, the problem of underrepresentation of minorities in clinical trials...
persists [3,4]. New strategies are required to improve recruitment of underrepresented populations into cancer clinical trials. The Internet is a logical resource for clinical trial advertisement and recruitment as almost 86% of the U.S. population has regular access to the Internet [5]. Importantly, African Americans and Latinos have doubled their use of the Internet in the last decade [6,7], making it a potentially important tool in strategies designed to increase participation of these underrepresented groups.

Although several Internet-based clinical trial matching tools have been developed, these tools are limited in scope and not designed to be patient-friendly [8,9]. Users typically receive a list of trials with principal investigator (PI) or site contact information, and eligibility criteria are described in complex medical jargon. Some tools offer limited custom matching of individuals to trials, but these often require registration. Most tools are only available in English, which may limit minority participation, and many are not tailored to individuals with limited health literacy. A national database of clinical trials that was developed to facilitate enrollment showed a positive impact on matching and recruiting patients into prevention trials; however, this database did not facilitate final enrollment [10], suggesting a need for further engagement (e.g., personal interaction) and patient navigation once a possible match is identified [10–12]. Additionally, a study of users of a breast cancer clinical trials matching tool showed that those who did not find their match results “relevant” cited that most of the trials matched to them were located far away [13]. Finally, most existing clinical trial matching tools lack an individualized service that could answer patients’ or family members’ questions. Some sites may offer a phone service, though this is meant to guide callers through the matching process without offering additional information about the trial or alternatives to participating in the trial. These limitations result in inadequate recruitment and enrollment of diverse, low-literacy patients into cancer clinical trials.

The utility of the Internet to disseminate health information to minority Americans was recognized early on [14]; however, little is understood regarding the online research-seeking behavior of underrepresented populations within the United States. Frameworks generated from the field of internet technology adoption could be extrapolated to better understand the development of utilizing matching tools to increase participation in clinical trials [15]. The development of matching tools was broadly based on the technology acceptance model which proposes that the perceived usefulness and the perceived ease-of-use of the new technology are essential elements for its adoption [16]. These two elements were essential in the development of this internet-based matching tool intervention.

To address these issues of inadequate recruitment efforts of diverse patients in clinical trials, we evaluated the feasibility (tested in a limited way) [14], acceptability (by the intended audience) [14], and initial measures of efficacy of an English and Spanish, multilevel recruitment intervention. This pilot study was conducted at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center (HDFCCC), using prostate cancer clinical trials. We hypothesized that pairing a matching tool with personalized navigator services to assist patients through trial selection and enrollment was likely to enhance participation [12,17], as navigator services embedded in cancer care have had positive effects on clinical trial recruitment [15,18]. Thus, in addition to a low-literacy, bilingual (English and Spanish) Internet-based clinical trial matching tool, we included a bilingual nurse navigator to facilitate enrollment. To attract users, particularly minorities, to this the matching tool, we initiated a broad community-based Internet advertising campaign.

2. Materials and methods

2.1. Study setting

The study was conducted between October 1, 2014 and April 15, 2015. The Spanish version of the matching tool was initiated on March 1, 2015 and was maintained until the end of the study. The Internet-based matching tool was available to anyone with Internet access, using standard search engines, or by the user selecting an advertisement on prostate cancer-related UCSF websites. The active Google AdWords advertising campaign (described below) was geographically targeted to the San Francisco Bay Area, with a particular focus on areas and neighborhoods with higher proportions of Latino and African American residents based on census data. The study was approved by the UCSF Institutional Review Board.

2.2. Description of intervention

The intervention consisted of three components: 1) a low-literacy, bilingual (English and Spanish), automated, Internet-based clinical trial matching tool; 2) a bilingual nurse who assisted interested individuals with questions and facilitated enrollment into clinical trials; and 3) a broad community-based Internet advertising campaign.

2.2.1. Internet-based clinical trial matching tool

The Internet-based clinical trial matching tool used in this study, which was hosted on a UCSF-supported website, was designed to be accessible to patients with limited health literacy and to present the fewest barriers to participation. The matching tool, which was embedded in the HDFCCC homepage, did not require registration, was offered in English and Spanish, asked the minimum number of questions needed to match participants to trials, and was programmed to offer only those trials tailored to the patient's personal prostate cancer characteristics. The tool's website and algorithm were built using the Qualtrics Research Suite, a HIPAA-compliant cloud-based survey program. Individuals arrived at the matching tool by clicking on either the link embedded in the HDFCCC website, searching for clinical trials using any internet search engine, clicking on our study's advertisement (when the Google AdWords advertising campaigns were active), or from other sources (e.g., word of mouth, etc.). At any given point during the study period, there were 17 interventional clinical trials for patients with various stages of prostate cancer open for accrual at UCSF.

Patients using the Internet-based matching tool, or family members or friends using the tool on the patient's behalf, were asked to complete a brief assessment to determine the patient's eligibility for the available clinical trials. To further maximize inclusion, in addition to applying a registration-free platform, we utilized only a small number of the most relevant screening questions. Considering our goal of serving low health literacy participants, we anticipated that not all respondents would have complete information about the patient's disease characteristics or medical history. Thus, we were concerned that using an “inclusion-only” algorithm (that is, individuals must fit all criteria that a specific clinical trial requires) would inadvertently screen out otherwise appropriate participants from clinical trials. Instead, we used a “non-exclusion” algorithm, whereby participants were deemed as “possibly matched” to a trial unless they specifically reported clinical information that would make them ineligible. To maximize the chances of including all patients who were potentially eligible for a trial, we asked about broad health criteria rather than more specific disease characteristics.

The matching algorithm used all available clinical data from the participant to match them to active trials at UCSF and displayed summaries of each trial to which an individual had been matched. All summaries were written at a sixth-grade reading level in both Spanish and English and presented in a clear, simple format. To minimize confusion, each summary was displayed on a separate page. Both general information and trial-specific details about eligibility, benefits, risks, and procedures were included. After each summary, participants were asked whether they were interested in the trial. Users who indicated interest in any matched trial were given an opportunity to submit their name, phone number, and other contact information. If contact information was submitted, an automated email containing the
relevant user information (contact information, clinical data, possible matches, interest indicated) was sent to the nurse navigator. Users for whom no match was found were informed of their ineligibility for any current trials and presented with links to other UCSF and National Cancer Institute resources. Patients or their family members who requested information were given a telephone number or an email where they could send a request.

2.2.2. Bilingual nurse navigator

An oncology nurse, bilingual in Spanish and English, was assigned to respond to phone and email requests from users of the matching tool. The nurse responded to participants based on their answers to the screening items, including information on the participant’s diagnosis and health characteristics, knowledge of clinical trials, and potential barriers to participation. The nurse further assessed and confirmed eligibility for specific trials, provided additional verbal and/or written information about trials, and facilitated recruitment visits with appropriate clinical trial investigators. For this study, the nurse’s role was solely to provide information to facilitate the participants’ personal decision-making. The nurse navigator was not a member of any study team associated with specific clinical trials.

2.2.3. Internet-based advertising campaign

To increase community participation in prostate cancer clinical trials, and especially the participation of minorities, an Internet-based advertising campaign targeting the greater San Francisco Bay Area was developed. The advertising campaign was launched using Google AdWords, a fee-based service. AdWords bypasses Google's PageRank search result algorithm by displaying a specific advertisement (“ad”) link among search results to the right of the page when an individual enters predetermined keywords into a Google search query (e.g., prostate clinical trial). By clicking on a study ad, the user was directed to the matching tool site. AdWords can geographically target ads, with some precision, based on the Internet Protocol (IP) address of the user’s device, which in turn is based on specific zip codes or a custom radius around arbitrary geographical coordinates. For mobile devices, Global Positioning Service (GPS) and cell towers are used to determine the current geographical location of the device, triggering ads relevant to that location. For this study, ads were targeted to the San Francisco Bay Area and specifically to those areas with a larger proportion of African-American, Latino, and Asian-American residents. The ads were run for three separate periods: October 28, 2014 to November 3, 2014 (one-week test), January 21, 2015 to February 12, 2015 (three weeks and 2 days), and March 12, 2015 to April 6, 2015 (three weeks and 5 days). Within all three periods, ads were run in English; Spanish ads ran only during the last period. The ads automatically took the user to the matching tool in the same language as the ad. The ads contained a brief description of the clinical trial matching tool. Using various keywords and groups of ads, AdWords allowed us to closely monitor the performance of individual ads and keywords (i.e., which ads or keywords were more likely to result in a site visit). Ineffective ads and keywords were eliminated in favor of better performing ones [19].

2.3. Measures

2.3.1. Demographic indicators

We collected demographic information about each person who used the matching tool: whether the user currently had prostate cancer or was a friend or family member of someone who was diagnosed with prostate cancer; age (categorized as ≤39, 40–75 years, 76–85, >85); self-reported race/ethnicity (non-Latino white, Latino, African American, Asian or Pacific Islander, or American Indian and other groups); education level (high school/GED or less, some college or associate degree, bachelor’s degree, or graduate education, and current or past utilization of UCSF medical center as a cancer care provider.

2.3.2. Health literacy

Health literacy was assessed with using three validated questions to determine the following: (1) the frequency with which the patient required a family member, friend, hospital worker, or caregiver to help read hospital materials; (2) the patient’s concerns regarding a lack of understanding of his own medical condition due to difficulty understanding written information; and (3) the patient’s level of discomfort with filling out medical forms alone [20,21]. Response categories for each item ranged from always (1) to never (5). We dichotomized responses to “always/often/sometimes” versus “rarely/never.”

2.3.3. Health indicators

The following prostate cancer-related indicators were included in the analysis: time since diagnosis (≤6 months, >6 months, or not sure); PSA level at diagnosis (<10 ng/ml, ≥10 ng/ml, or not sure); current PSA level status (increasing versus decreasing, or not sure); Gleason score (6, 7, ≥ 8, or not sure); whether or not the cancer had spread (metastasized to lung, liver, bone, and/or brain; cancer has not metastasized; not sure); prior prostate cancer treatments if any (prostate surgery, internal or external radiation therapy, hormone therapy injections, hormone therapy pills, chemotherapy, or cryosurgery).

2.3.4. Outcome indicators

The feasibility of this study was assessed with several outcomes: 1) completion of the matching tool, 2) expression of interest in a clinical trial by providing contact information, and 3) matching to a clinical trial. The effect of the Internet-based advertising campaign on the use of the matching tool was also evaluated. Potential impact of the intervention was assessed among those participants who provided contact information via follow-up qualitative interviews. We assessed discussion of risks and benefits of clinical trial participation with a physician and subsequent clinical trial participation. These patients were called once a week until contacted or until three attempts had been made without response. For patients who received medical care at UCSF, we assessed whether they participated in a clinical trial. We assessed the acceptability of the study by examining participants’ feedback. We inquired about participants’ thoughts about the matching program, including whether (a) the site was easy to use, (b) the matching results were useful, and (c) the information was easy to understand. Response options included “yes,” “somewhat,” and “no.”

2.4. Statistical analysis

Descriptive statistics were used to characterize users who were identified as having a prostate cancer diagnosis. Among participants with prostate cancer, bivariate analyses compared demographic and clinical characteristics of those who matched to at least one clinical trial compared to those who did not. Among those who matched to a clinical trial, we compared those who provided contact information versus those who did not. In addition, we compared the demographic characteristics of those who completed the tool during the Google AdWords campaign versus those who completed the tool outside the ad campaign period. Chi-square tests were carried out to assess any significant differences between categorical variables, and t-tests were used to assess differences in continuous variables (two-tailed significance level p < 0.05).

3. Results

3.1. Characteristics of participants

During the 28-week study period, 523 of those who responded completed at least some demographic information. Of these, 263 (50.2%) identified themselves as having prostate cancer (Table 1). Approximately two-thirds (64.6%) of participants with prostate cancer answered the questions for themselves, whereas over a third (35.4%)
were doing so on behalf of someone with the disease. Most (84.4%) were between the ages of 40 and 75 years old. More than three-quarters (75.7%) of these participants identified as non-Latino white, 6.8% as Asian American, 6.8% as Latino, and 4.2% as African American.

The number of Latino respondents with prostate cancer who used the matching tool increased considerably once the Spanish-language version of the tool was launched. During a 21 ½-week period when the matching tool was available only in English, 5 (3.3%) respondents noted their PSA score was climbing (Table 2). Over a third (35.4%) of the participants reported a Gleason Score ≥ 8, and 31.2% indicated their cancer had not metastasized.

Among those who matched to a clinical trial (n = 192), nearly three-quarters (73%) matched to at least one trial and the median number of matched trials was 3, with a mean of 3.5 (SD = 2.2; range 1–10). Among the 29 men with prostate cancer who provided contact information (15.1%), the median number of trials was 3, with a mean of 3.4 (SD = 2.1; range 1–7).

### Table 1: Characteristics of participants who identified with prostate cancer.

| Characteristics                          | Identified with Prostate Cancer | Matched V. Not Matched to a Trial | Contact Information among Matched Participants |
|-----------------------------------------|--------------------------------|-----------------------------------|-----------------------------------------------|
|                                         | N = 263                        | N = 71 27%                        | N = 163 84.9%                                 |
| Education                               | %                              | %                                 | %                                             |
| High school/GED                         | 10.3                           | 13.0                              | 10.0                                          |
| Some college or AA                      | 19.8                           | 27.5                              | 15.6                                          |
| Bachelor’s degree                       | 26.6                           | 20.3                              | 28.7                                          |
| Graduate education                      | 41.4                           | 39.1                              | 45.6                                          |
| Missing                                 | 1.9                            | –                                 | –                                             |
| Health Literacy (always, often, sometimes) |                                |                                   |                                               |
| Needs help reading materials            | 24.0                           | 42.4                              | 18.1                                          |
| Difficulty understanding written materials                                                                 | 42.4, 18.5                     | 27.0, 0.001                       | 26.9, 0.05                                   |
| Not comfortable filling out medical forms | 16.9                           | 25.8                              | 12.5, 0.05                                   |
| UCSF Patient                            |                                |                                   |                                               |
| No                                      | 67.6                           | 58.2                              | 71.4                                          |
| No, but I have been one                 | 16.0                           | 20.9                              | 13.0                                          |
| Yes                                     | 14.1                           | 20.9                              | 15.5                                          |
| Missing                                 | 2.3                            | –                                 | –                                             |

### 3.2. Matching to trials

There were 17 prostate cancer clinical trials available over the course of the study for participants to be matched to during the study period (between 8 and 12 trials were open at any given point during the study), and 73% of men with prostate cancer matched to at least one of these trials. Among those who matched to a clinical trial (n = 192), nearly three-quarters (73%) matched to at least one trial and the median number of matched trials was 3, with a mean of 3.5 (SD = 2.2; range 1–10). Among the 29 men with prostate cancer who provided contact information (15.1%), the median number of trials was 3, with a mean of 3.4 (SD = 2.1; range 1–7).

#### 3.2.1. Participants who matched to a clinical trial

Participants who matched to a clinical trial were significantly less likely to report for themselves, (30.2% versus 49.3% p < 0.01) and more likely to be white (78.1 versus 69.0 p < 0.05) compared to those who did not match to a trial (Table 1). In addition, those who matched were less likely to need help reading materials (18.5% versus 42.4% p < 0.0001), to have difficulty understanding written materials (27.0% versus 42.4% p < 0.05), and to feel uncomfortable filling out medical forms (13.8% versus 25.8%, p < 0.05).

There were also several significant clinical differences between the men who matched to at least one clinical trial and those who did not match (Table 2). Men who matched were significantly more likely to be diagnosed within six months of using the matching tool (42.7% versus 61.6% p < 0.05), were less likely to be diagnosed more than a third (30.1%) of participants reported having less than a bachelor’s degree. A quarter (24.0%) of participants reported needing help reading materials given to them by a doctor or hospital, 32.0% reported they had at least some difficulty understanding written materials regarding their medical condition, and 16.9% reported not being comfortable filling out medical forms by themselves.

As for clinical characteristics, more than a third (36.1%) of the participants with prostate cancer received the diagnosis within the past six months, 36.1% reported a PSA score of ≥10 ng/mL, and 56.7% noted their PSA score was climbing (Table 2). Over a third (35.4%) of the participants reported a Gleason Score ≥ 8, and 31.2% indicated their cancer had not metastasized. Among those who reported prior treatment, 19.2% reported undergoing prostate surgery, 25.1% radiation therapy, 33.9% hormone therapy injections, 23.0% hormone therapy pills, 13.5% chemotherapy, and 1.5% cryosurgery.
21.3%, \( p < 0.0001 \)), to have PSA levels lower than 10 ng/mL (63.0% versus 36.1%, \( p < 0.0001 \)), and to report no metastasis (40.1% versus 7.0%, \( p < 0.0001 \)). They also were less likely to report hormone therapy injections (26.5% versus 53.6%, \( p < 0.0001 \)), hormone therapy pills (13.4% versus 48.6%, \( p < 0.0001 \)), and receipt of chemotherapy (3.7% versus 40.6%, \( p < 0.0001 \)).

### 3.2.2. Participants who provided contact information

Among men who matched to at least one trial, men who provided contact information were not significantly different from those who did not provide information with one exception: Men who left contact information were less likely to report higher Gleason scores (≥8) than those who matched to a clinical trial (51.8 versus 45.7, \( p < 0.01 \)).

### 3.3. Reach of Google AdWords

**Fig. 1** shows the effect of the Internet ad campaigns on matching tool usage. The ad campaign was active in three separate phases for 7 of the 28 total weeks of the pilot study. Overall, the campaign increased the number of individuals with prostate cancer who completed the matching tool and who provided contact information. Over half of the participants reaching the study came via clicking on a Google AdWords ad (51.8% versus 45.7, \( p < 0.0001 \)), despite the ads running for less than 25% of the study time period. The average number of matching tool completions per week was 1.1 during weeks when the ads were not running compared to 9.0 per week when the ads were active. The number of people interested in clinical trial participation, measured by those who left contact information, increased as well. During weeks when ads were running, on average, 1.17 participants per week provided contact information compared to 0.07 participants per week when ads were not running.

The study spent approximately $500 per week when ads were running. The most used keywords were prostate cancer clinical trials, prostate, clinical trials, prostate cancer treatment, and prostate tumor. Comparison of demographic characteristics between those who responded during Google AdWords period and those who responded outside the ad periods indicates that there were no significant differences between the two groups with one exception: Those who answered the ads were more likely to have experienced prostate cancer themselves (Table 3).

### 3.4. Contact, follow-up interviews, and participation in clinical trials

Twenty-nine participants provided their contact information, three of whom died sometime between their use of the tool and our attempts to contact them for a follow-up interview. We completed 14 follow-up interviews (48.3% response rate). Based on the interview data, it was determined that 12 of 14 (85.7%) interview participants discussed the risks and benefits of enrolling in a clinical trial either with their primary care physician or a UCSF oncologist. Five men enrolled in a clinical trial, three of whom did so at UCSF. This represents a 35.7% participation rate in all trials regardless of location (5/14) and a 21.4% participation rate in UCSF clinical trials (3/14) among those who completed follow-up interviews.

---

### Table 2

Clinical characteristics of participants who identified with prostate cancer.

| Identified with Prostate Cancer | Matched V. Not Matched to a Trial | Contact Information among Matched Participants |
|--------------------------------|----------------------------------|-----------------------------------------------|
|                                | N = 263                          | N = 192                                       |
|                                | No Match Matched P Value         | Did Not Provide Information Provided Information P Value |
|                                | % % %                           | % %                                           |
| Time since Cancer Diagnosis    |                                   |                                               |
| 6 months ago or less           | 36.1 21.3 42.7 < 0.0001          | 41.7 48.3 ns                                 |
| More than 6 months ago         | 58.9 73.8 57.3                  | 58.3 51.7                                    |
| Not sure                       | 1.1 4.9 0.0                     | – –                                          |
| Missing                        | 3.8                              | – –                                          |
| PSA Level at Diagnosis         |                                   |                                               |
| < 10 ng/mL                     | 54.4 36.1 63.0 < 0.0001          | 66.3 44.8 ns                                 |
| ≥ 10 ng/mL                     | 36.1 50.8 33.3                  | 30.1 51.7                                    |
| Not sure                       | 5.7 13.1 3.6                    | 3.6 3.5                                       |
| Missing                        | 3.8                              | – –                                          |
| PSA Level Status               |                                   |                                               |
| Increasing                     | 56.6 64.7 62.7 ns               | 63.1 60.7 ns                                 |
| Decreasing                     | 12.2 21.6 11.4                  | 11.5 10.7                                    |
| Unchanged                      | 12.2 7.8 15.1                   | 14.6 17.9                                    |
| Not sure                       | 8.7 5.9 10.8                    | 10.8 10.7                                    |
| Missing                        | 10.3                             | – –                                          |
| Gleason Score                  |                                   |                                               |
| 6                              | 14.7 3.6 19.4 < 0.0001          | 22.2 3.5 < 0.01                              |
| 7                              | 22.1 10.9 27.2                 | 23.5 48.3                                    |
| ≥ 8                            | 35.4 54.5 33.0                  | 34.6 24.1                                    |
| Not sure                       | 21.3 36.9 20.4                 | 19.7 24.1                                    |
| Missing                        | 6.5                              | – –                                          |
| Cancer Spread                  |                                   |                                               |
| No metastases                  | 31.2 7.0 40.1 < 0.0001          | 42.9 24.1 ns                                 |
| Metastasis                     | 68.8 93.0 59.9                 | 57.1 75.9 ns                                 |
| Prior Prostate Cancer Treatment|                                   |                                               |
| Prostate surgery               | 19.2 17.1 19.9 ns               | 19.1 24.1 ns                                 |
| Radiation therapy              | 25.1 31.0 22.9 ns               | 22.1 27.6 ns                                 |
| Hormone therapy injections     | 33.9 53.6 26.5 < 0.0001         | 24.4 37.9 ns                                 |
| Hormone therapy pills          | 23.0 48.6 13.4 < 0.0001         | 12.7 17.2 ns                                 |
| Chemotherapy                   | 13.5 40.6 3.7 < 0.0001          | 3.7 3.4 ns                                   |
| Cryosurgery                    | 1.5 0.0 2.1 ns                 | 1.9 3.4 ns                                   |

---

\( p < 0.0001 \), to have PSA levels lower than 10 ng/mL (63.0% versus 36.1%, \( p < 0.0001 \)), and to report no metastasis (40.1% versus 7.0%, \( p < 0.0001 \)). They also were less likely to report hormone therapy injections (26.5% versus 53.6%, \( p < 0.0001 \)), hormone therapy pills (13.4% versus 48.6%, \( p < 0.0001 \)), and receipt of chemotherapy (3.7% versus 40.6%, \( p < 0.0001 \)).
included limitations imposed by third party insurance, travel distance, and lack of information and/or contact from UCSF personnel. Enrollment in a trial somewhere other than UCSF by men who did not make an appointment at UCSF or who were not reached by telephone or e-mail for a follow-up interview could not be determined.

3.5. Feedback on the matching program

Forty-nine participants provided feedback on the Internet-based clinical trial matching tool. Of those, almost all (98%) reported the site was easy to use. Three-quarters (74.5%) found the matching results useful, while 19.1% found them somewhat useful. Almost all the respondents (97.9%) reported that the information provided was easy to understand.

4. Discussion

This pilot study provided evidence that an automated, Internet-based clinical trial matching tool with targeted Internet-based advertising is feasible, acceptable, and effective in reaching men with prostate cancer. In addition, this study demonstrated that geographic targeting and the use of Spanish-language matching tool and advertisements increased the proportion of Latino participants. These findings are supported by similar studies examining Internet matching tools [22]. However, our study population was 25% non-white compared to 10% in similar matching studies and was able to reach a higher proportion of minority populations [22]. Spratt and colleagues reported that African American men comprise about 3.3% of phase III randomized clinical trials in prostate cancer [23]. Our study found that 5.1% of participants who used the matching tool when the Google AdWords campaign was live identified as African American. The targeted geographical areas and diversity of the Northern California population, as well as the effort to target the Latino population, may account for these discrepancies.

This approach was relatively easy to implement, leveraging available off-the-shelf technology. A widely used Qualtrics survey platform was employed to construct a simple website, which included a matching tool algorithm that required minimal upkeep. The feasibility and applicability of this model is reflected, in part, by the resource efficiency of the program. Although initial efforts are required to design the questionnaire, program the Internet-based tool, and prepare the trial summaries provided to participants, maintenance further along is required only as trials open and close.

The matching tool was designed to reduce participant burden while broadening their options. This approach matched participants to trials fitting their specific clinical situation. This is different from other algorithms that only roughly match a participant’s condition to a clinical trial. For example, traditional matching to the extent of disease (e.g., metastatic prostate cancer) critically misses hormonal status (sensitive or resistant), which is an equally important determinant of trial eligibility. Conversely, this tool avoided overemphasis on granular clinical details to eliminate a potential source of participant frustration and to minimize risk of inaccurate responses, limiting the relevance of participant-trial matches. This approach generated a broad yet relevant list of trials for each participant, allowing for a greater choice and more information regarding potential trials. Additionally, participants who used the matching tool found it easy to navigate and did not identify complexity of the language nor the amount or length of questions as barriers to participation.

This approach is among the first to implement Spanish-language
support along with IP-address targeted advertising in an effort to increase clinical trial access among underrepresented minorities. When Spanish-language version was run, the proportion of Latino respondents more than tripled, from 9% to 30%. When implemented at scale and the broad reach of the Internet-based tool, and therefore the potential recruitment strength of this program, are reflected in the number of total users who completed the matching tool. Ultimately, this program served as an additional avenue through which patients, especially those who may not have considered a clinical trial as a viable option, were able to access trial participation. Today, online health information resources for a diverse population of men with prostate cancer are limited. While caution for the digital divide may have exacerbated disparities in health information resources, this study highlights the acute need for and investment in more robust Internet health information infrastructure. Future studies will need to deliver more comprehensive online resources for a diverse population of men with prostate cancer.

Table 3
Participants’ characteristics during and outside of Google Ad periods.

|                      | Outside of Google | During Google | P Value |
|----------------------|-------------------|---------------|---------|
| Ad Period            | Ad Period         |               |         |
| N = 263              | N = 105 39.9%     | N = 158 60.1% |         |
| %                    | %                 | %             |         |

**Individual Completing Matching Tool Survey**

- Self: 57.1 vs. 69.6, < 0.05
- Someone else: 42.9 vs. 30.4, ns
- If someone else, family member or friend: 88.6 vs. 89.6, ns

**Ethnicity**

- Non-Latino white: 77.1 vs. 74.6, ns
- Latino: 6.6 vs. 7.0
- African American: 2.9 vs. 5.1
- Asian or Pacific Islander: 12.4 vs. 9.5
- American Indian and other: 1.0 vs. 3.8

**Age**

- ≤ 39 years: 0.0 vs. 1.3, ns
- 40–75 years: 88.6 vs. 81.6
- 76–85 years: 11.4 vs. 12.0
- > 85 years: 0.0 vs. 5.1

**Education**

- High school/GED or less: 7.8 vs. 12.2, ns
- Some college or AA: 17.6 vs. 21.8
- Bachelor’s degree: 22.5 vs. 30.1
- Graduate education: 52.0 vs. 35.9

**Health Literacy (always, often, sometimes)**

- Needs help reading materials: 26.0 vs. 23.8, ns
- Difficulty understanding written materials: 30.8 vs. 31.1, ns
- Not comfortable filling out medical forms: 13.5 vs. 19.2, ns

**UCSF Patient**

- No: 63.1 vs. 73.4, ns
- No, but I have been one: 19.4 vs. 14.3
- Yes: 17.5 vs. 12.3

5. Conclusions

In summary, this pilot program has shown that a personalized, questionnaire-based online approach (i.e., the matching tool), can improve access and potentially facilitate enrollment among individuals who may not participate in clinical trials. Both the ease of use and the broad reach of the Internet-based tool, and therefore the potential recruitment strength of this program, are reflected in the number of total users who completed the matching tool. Ultimately, this program served as an additional avenue through which patients, especially those who may not have considered a clinical trial as a viable option, were able to access trial participation. Today, online health information resources for a diverse population of men with prostate cancer are limited. While caution for the digital divide may have exacerbated disparities in health information resources, this study highlights the acute need for and investment in more robust Internet health information infrastructure. Future studies will need to deliver more comprehensive online resources for a diverse population of men with prostate cancer.

Conflict of interest disclosure

The authors have no conflicts of interest to disclose.

Role of the funding source(s)

The funding sources had no role in the study design; the collection, analysis, or interpretation of data; the writing of the report; or the decision to submit the article for publication.

Acknowledgements

Thank you to Gerinoma Cortese, UCSF Urology Nurse Navigator, and Andrew Rodriguez, UCSF Clinical Research Coordinator. This research was funded by the Mt. Zion Health Fund, number 4300, at UCSF.

References

[1] L. Ford, A.D. Kaluzny, E. Sondik, Diffusion and adoption of state-of-the-art therapy,
[2] V.H. Murthy, H.M. Krumholz, C.P. Gross, Participation in cancer clinical trials: race-, sex-, and age-based disparities, Jama 291 (22) (2004) 2720–2726.
[3] H.P. Freeman, The impact of clinical trial protocols on patient care systems in a large city hospital access for the socially disadvantaged, Cancer 72 (59) (1993) 2834–2838.
[4] D.P. Wermeling, A.S. Selwitz, Current issues surrounding women and minorities in drug trials, Ann. Pharmacother. 27 (7–8) (1993) 904–911.
[5] J. Poulter, C. Bishop, H. Chwe, Social Media Use Continues to Rise in Developing Countries but Plateaus across Developed Ones, (2018).
[6] A. Brown, G. Lopez, M.H. Lopez, Digital Divide Narrows for Latinos as More Spanish Speakers and Immigrants Go Online, Pew Institute, 2016.
[7] A. Smith, African Americans and Technology Use: a Demographic Portrait, Pew Research Center, 2014.
[8] P.P. Breitfeld, et al., Pilot study of a point-of-use decision support tool for cancer clinical trials eligibility, J. Am. Med. Inf. Assoc. 6 (6) (1999) 466–477.
[9] N.L. Atkinson, et al., User-centered research on breast cancer patient needs and preferences of an internet-based clinical trial matching system, J. Med. Internet Res. 9 (2) (2007) e13.
[10] J.M. Metz, et al., An internet-based cancer clinical trials matching resource, J. Med. Internet Res. 7 (3) (2005).
[11] S.J. Wei, et al., Recruitment of patients into an internet-based clinical trials database: the experience of OncoLink and the national colorectal cancer research alliance, J. Clin. Oncol. 22 (23) (2004) 4730–4736.
[12] M.N. Fouad, et al., Patient navigation as a model to increase participation of African Americans in cancer clinical trials, J. Oncol. Pract. 12 (6) (2016) 556–563.
[13] E.J. Cohen, BreastCancerTrials.org: development of a patient-centered clinical trial matching service, Breast Dis. Year Bk. Q.: Year Bk. Q. 22 (4) (2011) 352–354.
[14] D.J. Bowen, et al., How we design feasibility studies, Am. J. Prev. Med. 36 (3) (2009) 452–457.
[15] M.E. Ford, et al., Unequal burden of disease, unequal participation in clinical trials: solutions from African American and Latino community members, Health Soc. Work 38 (1) (2013) 29–38.
[16] P. Legris, et al., Why do people use information technology? A critical review of the technology acceptance model, Inf. Manag. 40 (3) (2003) 191–204.
[17] B.A. Guadagnolo, et al., Involving American Indians and medically underserved rural populations in cancer clinical trials, Clin. Trials 6 (6) (2009) 610–617.
[18] D.B. Holmes, et al., Increasing minority patient participation in cancer clinical trials using oncology nurse navigation, Am. J. Surg. 203 (4) (2012) 415–422.
[19] M.S. Gross, et al., Using Google AdWords for international multilingual recruitment to health research websites, J. Med. Internet Res. 16 (1) (2014).
[20] L.D. Chew, K.A. Bradley, E.J. Boyko, Brief questions to identify patients with inadequate health literacy, Health 11 (2004) 12.
[21] L.D. Chew, et al., Validation of screening questions for limited health literacy in a large VA outpatient population, J. Gen. Intern. Med. 23 (5) (2008) 561–566.
[22] J.M. Metz, et al., An internet-based cancer clinical trials matching resource, J. Med. Internet Res. 7 (3) (2005).
[23] D.E. Spratt, J.R. Osborne, Disparities in castration-resistant prostate cancer trials, J. Clin. Oncol. 33 (10) (2015) 1101.